Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Catalent, Inc.    CTLT

CATALENT, INC.

(CTLT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/19/2020 02/20/2020 02/21/2020 02/24/2020 02/25/2020 Date
60.65(c) 58.8(c) 58.98(c) 55.92(c) 54.72(c) Last
2 306 730 732 427 788 704 1 123 650 1 265 278 Volume
+2.28% -3.05% +0.31% -5.19% -2.15% Change
More quotes
Financials (USD)
Sales 2020 2 910 M
EBIT 2020 540 M
Net income 2020 177 M
Debt 2020 2 560 M
Yield 2020 -
Sales 2021 3 171 M
EBIT 2021 603 M
Net income 2021 233 M
Debt 2021 2 324 M
Yield 2021 -
P/E ratio 2020 50,8x
P/E ratio 2021 39,8x
EV / Sales2020 3,79x
EV / Sales2021 3,41x
Capitalization 8 474 M
More Financials
Company
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation,... 
Sector
Pharmaceuticals
Calendar
02/25 | 10:00amPresentation
More about the company
Surperformance© ratings of Catalent, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CATALENT, INC.
02/25CATALENT : Senior Vice President and Chief Financial Officer, Wetteny Joseph, In..
AQ
02/24CATALENT : Senior Vice President & Chief Financial Officer, Wetteny Joseph, Indu..
PU
02/20CATALENT : Announces Upsizing and Pricing of Private Offering of Senior Unsecure..
BU
02/19CATALENT, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/19CATALENT : Announces Launch of Private Offering of €450 Million of Senior Unsecu..
BU
02/18CATALENT, INC. : to Present at the 9th Annual SVB Leerink Global Healthcare Conf..
BU
02/13CATALENT : Appoints Jim Walter as Vice President of Operations for Oral and Spec..
AQ
02/12CATALENT : and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb t..
AQ
02/10CATALENT : Completes Acquisition of MaSTherCell
BU
02/10CATALENT : Recognized as a Country Certified Top Employer 2020
PU
02/06CATALENT, INC. : Entry into a Material Definitive Agreement, Financial Statement..
AQ
02/04ORGENESIS : Announces Agreement for the Sale of Masthercell Global, its Contract..
AQ
02/03CATALENT, INC. : Announces Pricing of Public Offering of Common Stock
BU
02/03CATALENT, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/03CATALENT, INC. : Announces Public Offering of Common Stock
BU
More news
News in other languages on CATALENT, INC.
01/29CATALENT, INC. : Veröffentlichung des Halbjahresergebnisses
01/29CATALENT, INC. : publication des résultats semestriels
2019CYCLE PHARMACEUTICALS : und Catalent nutzen Zydis ODT-Technologie bei der gemein..
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on CATALENT, INC.
More recommendations
Sector news : Pharmaceuticals - NEC
02/25Soybeans Claw Back Some Coronavirus Losses
DJ
02/25Apple, J&J to study if Apple Watch app leads to lower stroke risk
RE
02/25DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/25ALLERGAN : Form 8.3 -
DJ
02/25ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart CATALENT, INC.
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 70,88  $
Last Close Price 54,72  $
Spread / Highest target 37,1%
Spread / Average Target 29,5%
Spread / Lowest Target 22,4%
EPS Revisions
Managers
NameTitle
John R. Chiminski Chairman & Chief Executive Officer
Alessandro Maselli President & Chief Operating Officer
Wetteny Joseph CFO, Principal Accounting Officer & Senior VP
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CATALENT, INC.-2.81%8 474
JOHNSON & JOHNSON0.03%381 112
ROCHE HOLDING AG10.13%287 430
MERCK AND COMPANY-11.74%204 366
NOVARTIS2.72%201 414
PFIZER-11.51%187 773